Dr. Sohal on Perioperative mFOLFIRINOX in Pancreatic Adenocarcinoma

Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.

SWOG S1505 is one of the first cooperative group studies exploring this treatment in pancreatic cancer, Sohal explains. It is a shift from the standard of care for these patients, which is surgery followed by adjuvant chemotherapy with or without radiation therapy. However, research now shows that pancreatic cancer is a systemic disease and it should be targeted with aggressive systemic chemotherapy regimens upfront.

This is what this study is testing, Sohal adds—the efficacy, safety, and feasibility of this approach.